GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor;...

在與FDA會面後，glycomimetics將爲再發生的急性髓系白血病進行更多的臨床試驗。公司啓動戰略審查和企業重組，裁員80％；聘請Lucid資本市場作爲戰略顧問; ...

Benzinga · 07/25 21:01

GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor; Advancing Phase 2/3 Study Of Uproleselan In Newly Diagnosed AML Patients With NCI And Alliance For Clinical Trials; Cash Expected To Fund Company Into Q2 2025

glycomimetics將在與FDA會面後爲R/R急性髓系白血病的uproleselan開展額外的臨床試驗；啓動戰略審查和公司重組，將員工人數減少80%; 聘請Lucid資本市場作爲戰略顧問；與NCI和Alliance for Clinical Trials推進uproleselan用於新診斷的AML患者的2/3期研究；現金預計將支持公司到2025年第二季度。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。